ReviewJournal of neurology2026
Sporadic Creutzfeldt-Jakob disease: a multidimensional review from epidemiology to treatment and prognosis.
Review in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sporadic Creutzfeldt-Jakob disease (sCJD) is the most prevalent human prion disease, characterized by rapidly progressive neurodegeneration and an invariably fatal outcome. This review comprehensively examines the epidemiological features, molecular pathogenesis, clinical manifestations, diagnostic approaches-including neuroimaging, laboratory assays, cerebrospinal fluid analysis, and genotyping-and current therapeutic strategies alongside prognosis evaluation of sCJD. Despite advances in understanding prion biology and disease mechanisms, challenges remain in early diagnosis and effective treatment. Recent progress in biomarker discovery, refinement of diagnostic criteria, and emerging therapeutic interventions is highlighted to provide an integrated perspective on sCJD management. By synthesizing the latest research findings, this article aims to offer a thorough reference for clinicians and researchers, facilitating improved diagnostic accuracy and patient care, and guiding future investigations into this fatal neurodegenerative disorder.
Indexed as
Identifiers
42230352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.